The study, which is published online in Nature Medicine by scientists from University of Michigan Medical School and the Ludwig Institute at Karolinska Institutet, is performed on mice.
However, to test the theory in humans the researchers soon will begin a clinical trial in collaboration with the Karolinska University Hospital in Stockholm, using the leukemia drug known as imatinib (Glivec®).Their recent study on mice showed that the drug greatly reduces bleeding, even if tPA wasn't given until five hours after a stroke began.
"Ten years ago our research group identified the growth factor PDGF-CC, and we are now very excited having unraveled a mechanism in the brain involving this factor", comments the Karolinska Institutet team leader, Professor Ulf Eriksson. "This finding has indeed the potential to revolutionize the treatment of stroke."
The new paper details a series of molecular and cellular experiments conducted by the Swedish and American research teams, which began collaborating after hearing of each other's work. They report that tPA apparently causes its risk of bleeding, and leakage of fluid within the brain, by accident. The culprit is tPA's tendency to act upon a protein called PDGF-CC, and the PDGF-alpha receptor that it binds to. This interaction causes the usually impervious blood-brain barrier to become porous, leading to leakage.
Imatinib, however, inhibits the PDGF-alpha receptor permitting tPA to do its main job, which is to down clots that have lodged in the brain's blood vessels. If the clots are not removed, they will cut off blood supply and eventually starving brain tissue until it begins to die.
According to the World Health Organization (WHO), clots in the brain blood vessels causes 80 percent of the 15 million strokes that occur each year worldwide. Five million people die, and 5 million more are permanently disabled, by strokes each year.
"Our findings have immediate clinical relevance, and could be applied to find new treatments that will benefit stroke patients," says senior author, Professor Daniel Lawrence at the U-M Medical School. "By better understanding how the brain regulates the permeability of the blood-brain barrier, and how tPA acts upon that system, we hope to reduce the risks and increase the time window for stroke treatment."
Funding for the study came from the National Institutes of Health, the Ludwig Institute for Cancer Research at Karolinska Institutet, the Novo Nordisk Foundation, the Swedish Research Council, the Swedish Cancer Foundation, the LeDucq Foundation and the Inga-Britt and Arne Lundberg Foundation.
Publication: 'Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke', Enming J Su, Linda Fredriksson, Melissa Geyer, Erika Folestad, Jacqueline Cale, Johanna Andrae, Yamei Gao, Kristian Pietras, Kris Mann, Manuel Yepes, Dudley K Strickland, Christer Betsholtz, Ulf Eriksson och Daniel Lawrence Nature Medicine, AOP 22 June 2008, doi 10.1038/nm1787.For further information, please contact:
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences